Zobrazeno 1 - 10
of 217
pro vyhledávání: '"YINGQI HUA"'
Autor:
Jiachen Yu, Yuting Liu, Yingchun Zhang, Rong Ran, Zixiao Kong, Duoyi Zhao, Minda Liu, Wei Zhao, Yan Cui, Yingqi Hua, Lianbo Gao, Zhiyu Zhang, Yingxin Yang
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 11 (2024)
Introduction: Cancer remains a significant health challenge, with chemotherapy being a critical treatment modality. However, traditional chemotherapy faces limitations due to non-specificity and toxicity. Nanogels, as advanced drug carriers, offer po
Externí odkaz:
https://doaj.org/article/6e99ccd74935444888713ee3446e147b
Autor:
Hongsheng Wang, Xinmeng Jin, Yinghua Gao, Xin He, Yiming Xu, Haoran Mu, Yafei Jiang, Zhuoying Wang, Chen Yu, Tao Zhang, Yingqi Hua, Zhengdong Cai, Jing Xu, Xiaojun Ma, Wei Sun
Publikováno v:
Cancer Nanotechnology, Vol 14, Iss 1, Pp 1-21 (2023)
Abstract Background Tumor angiogenesis, immunosuppression, and progression are all closely correlated with the tumor microenvironment (TME). Immune evasion is supported by both M2 phenotype tumor-associated macrophages (TAMs) and vascular aberrations
Externí odkaz:
https://doaj.org/article/703eaaab943a43c8b659b42653154099
Autor:
Yafei Jiang, Jinzeng Wang, Mengxiong Sun, Dongqing Zuo, Hongsheng Wang, Jiakang Shen, Wenyan Jiang, Haoran Mu, Xiaojun Ma, Fei Yin, Jun Lin, Chongren Wang, Shuting Yu, Lu Jiang, Gang Lv, Feng Liu, Linghang Xue, Kai Tian, Gangyang Wang, Zifei Zhou, Yu Lv, Zhuoying Wang, Tao Zhang, Jing Xu, Liu Yang, Kewen Zhao, Wei Sun, Yujie Tang, Zhengdong Cai, Shengyue Wang, Yingqi Hua
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-17 (2022)
Osteosarcoma survival rates have been largely unchanged for several decades, and treatment response is variable. Here, the authors analyzed genomic, transcriptomic and epigenomic data from 121 osteosarcoma patients and identify subtypes related to tr
Externí odkaz:
https://doaj.org/article/a06bfe5476094b96b7cfb9ac4b5693ae
Inhibition of sphingolipid metabolism in osteosarcoma protects against CD151-mediated tumorigenicity
Autor:
Hongsheng Wang, Xinmeng Jin, Yangfeng Zhang, Zhuoying Wang, Tao Zhang, Jing Xu, Jiakang Shen, Pengfei Zan, Mengxiong Sun, Chongren Wang, Yingqi Hua, Xiaojun Ma, Wei Sun
Publikováno v:
Cell & Bioscience, Vol 12, Iss 1, Pp 1-14 (2022)
Abstract Osteosarcoma is the most common primary bone tumor, with a poor prognosis owing to the lack of efficient molecular-based targeted therapies. Previous studies have suggested an association between CD151 and distinct consequences in osteosarco
Externí odkaz:
https://doaj.org/article/130488c2f8504baaae40e7ac8f325dc2
Publikováno v:
Cancer Biology & Medicine, Vol 19, Iss 9, Pp 1397-1409 (2022)
Objective: Osteosarcoma (OS) is an aggressive, highly metastatic, relatively drug-resistant bone tumor with poor long-term survival rates. The presence and persistence of circulating tumor cells (CTCs) in the peripheral blood are believed to be assoc
Externí odkaz:
https://doaj.org/article/506573df04ee46e4863224441c64225d
Autor:
Mengxiong Sun, Zongyi Wang, Wei Sun, Ming Chen, Xiaojun Ma, Jiakang Shen, Zeze Fu, Dongqing Zuo, Gangyang Wang, Hongsheng Wang, Chongren Wang, Fei Yin, Zhuoying Wang, Chuanying Zhang, Yingqi Hua, Zhengdong Cai
Publikováno v:
Orthopaedic Surgery, Vol 14, Iss 6, Pp 1161-1166 (2022)
Objective To retrospectively analyze and compare the relationship between the success rate of patient‐derived xenograft (PDX) modeling of osteosarcoma and prognosis (3‐year overall survival rate and disease‐free survival rate) and incidence of
Externí odkaz:
https://doaj.org/article/9ffe1a1371d2493385a9f639387239a0
Autor:
Tao Zhang, Suoyuan Li, Jingjie Li, Fei Yin, Yingqi Hua, Zhuoying Wang, Hongsheng Wang, Dongqing Zuo, Jing Xu, Zhengdong Cai
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 153, Iss , Pp 113323- (2022)
Signal transducer and activator of transcription 3 (STAT3) plays essential roles in cancer progression and has been considered as a promising target for cancer therapy. Here, we used a dual luciferase assay to identify that pectolinarigenin inhibited
Externí odkaz:
https://doaj.org/article/dbe5466a0eb74f0e8e0f397e0d712b4c
Autor:
Haoran Mu, Chenlu Liu, Qi Zhang, Huanliang Meng, Shimin Yu, Ke Zeng, Jing Han, Xinmeng Jin, Shi Shi, Peiyao Yu, Tianlong Li, Jing Xu, Yingqi Hua
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 10 (2022)
Background: Drugs based on synthetic lethality have advantages such as inhibiting tumor growth and affecting normal tissue in vivo. However, specific targets for osteosarcoma have not been acknowledged yet. In this study, a non-targeted but controlla
Externí odkaz:
https://doaj.org/article/2275ca551cf24f12b7c841311e155fd9
Autor:
Mengkai Yang, Tao Zhang, Yangfeng Zhang, Xiaojun Ma, Jing Han, Ke Zeng, Yafei Jiang, Zongyi Wang, Zhuoying Wang, Jing Xu, Yingqi Hua, Zhengdong Cai, Wei Sun
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-15 (2021)
Abstract Background Osteosarcoma (OS) is the most common primary bone cancer in adolescents and lung metastasis is the leading cause of death in patients with OS. However, the molecular mechanisms that promote OS growth and metastasis remain unknown.
Externí odkaz:
https://doaj.org/article/84c8741d54b14955b81e72cfb96a2af5
Publikováno v:
Orthopaedic Surgery, Vol 13, Iss 2, Pp 616-622 (2021)
Objective Whether H3.3 K36M mutation (H3K36M) could be an approach if the diagnosis of chondroblastoma (CB) patients was indistinct and it was suspected to be unclear clinically. Methods We reviewed and compared our clinical experiences of CB cases a
Externí odkaz:
https://doaj.org/article/027cd753934d46358731c8ca86f307f5